Moniret (Dimetindene Maleate)

Dimetindene maleate blocks H1 histamine receptors on mast cells and peripheral nerves, preventing histamine‑induced vasodilation and nerve activation. Its anticholinergic and mast‑cell stabilising actions further limit the release of inflammatory mediators, resulting in reduced erythema, edema, and itch at the site of application.

The dosage of Moniret is determined by the prescribing healthcare professional based on the severity of the condition, patient age, and skin area to be treated. The prescriber will specify the amount to apply, frequency, and duration of therapy according to clinical guidelines.

Safety data for dimetindene maleate during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To order Moniret, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Moniret contains dimetindene maleate, a first‑generation H1 antagonist with added anticholinergic and mast‑cell stabilising properties. Compared with newer second‑generation topical antihistamines, it may have a higher potential for mild anticholinergic effects but offers rapid itch relief. Choice of product depends on clinician preference, patient tolerance, and specific skin condition.

Moniret should be stored below 25 °C in its original packaging, protected from moisture and direct light. Keep the container tightly closed when not in use. Do not freeze the product. Follow standard pharmacy handling procedures and keep out of reach of children.

Apply a thin layer of Moniret to clean, dry skin on the affected area, gently massaging it until absorbed. Avoid contact with eyes, mucous membranes, and broken skin unless directed by a healthcare professional. Frequency of application is determined by the prescriber, typically 1–3 times daily.

Serious but rare risks include severe allergic reactions such as angioedema or anaphylaxis, and systemic anticholinergic effects like pronounced dry mouth, blurred vision, urinary retention, or tachycardia. If any of these symptoms develop, discontinue use and seek immediate medical attention.

Moniret should be avoided in individuals with known hypersensitivity to dimetindene maleate or any excipients in the formulation. It is also contraindicated in patients with narrow‑angle glaucoma, severe urinary retention, or prostatic hypertrophy where anticholinergic effects could worsen the condition. Children under two years of age should not use it unless specifically prescribed.